Semaglutide and Cognition in Healthy Volunteers

NACompletedINTERVENTIONAL
Enrollment

70

Participants

Timeline

Start Date

June 6, 2024

Primary Completion Date

December 11, 2024

Study Completion Date

December 11, 2024

Conditions
Cognitive Change
Interventions
DRUG

Semaglutide, 0.5 mg/mL

Injected subcutaneously (pre-filled pen) in the upper arm (preferred site), in the abdomen, or in the thigh according to participant's preference. The participant will be asked to wear an eye blindfold during the time of the study medication/placebo administration, to avoid compromising blinding. It is not possible to blind the researcher administering the medication/placebo because semaglutide comes in specific pre-filled pens. The person who administers the subcutaneous injection will be suitably trained and experienced, and have been authorised to do so by the Principal Investigator - they will not be involved in other aspects of the study for that participant to avoid compromising blinding.

OTHER

Placebo, 0.9% NaCl 1.5mL

Injected subcutaneously (subcutaneous injection syringe) in the upper arm (preferred site), in the abdomen, or in the thigh according to participant's preference. The participant will be asked to wear an eye blindfold during the time of the study medication/placebo administration, to avoid compromising blinding. The person who administers the subcutaneous injection will be suitably trained and experienced, and have been authorised to do so by the Principal Investigator - they will not be involved in other aspects of the study for that participant to avoid compromising blinding.

Trial Locations (1)

OX3 7JX

Department of Psychiatry, University of Oxford, Oxford

All Listed Sponsors
collaborator

National Institute for Health Research, United Kingdom

OTHER_GOV

lead

University of Oxford

OTHER

NCT06363487 - Semaglutide and Cognition in Healthy Volunteers | Biotech Hunter | Biotech Hunter